Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Baseline tumor size as a prognostic index in patients with cancer receiving targeted agents

Paolo Tarantino • 5 Jun 2022
ASCO 2022
General

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the use of baseline tumor size as a prognostic index in patients with cancer receiving experimental targeted agents. Having lower amounts of disease was prognostically favorable with immunotherapy and targeted therapies, however, this is only true for biomarker-matched targeted therapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Paolo Tarantino

2:24
Breast cancer at ASCO 2023: NATALEE and sequencing ADCs
Paolo Tarantino • 5 Jun 2023
1:29
Takeaways on the management of early-stage TNBC
Paolo Tarantino • 5 Jun 2023
2:23
Prognosis and trends in chemotherapy use for patients with stage IA TNBC
Paolo Tarantino • 5 Jun 2023
4:08
SABCS 2022 highlights
Paolo Tarantino • 8 Dec 2022

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals